9:35–9:55

Abstract 8005

Erlotinib plus bevacizumab (EB)   versus erlotinib alone (E) as first-line treatment for advanced EGFR   mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An   open-label randomized trial.

厄洛替尼联合贝伐单抗对比厄洛替尼单药一线治疗EGFR突变的晚期、非鳞非小细胞肺癌：一项开放性的随机研究。

范  云(Yun Fan)

Abstract LBA8006^

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC)   and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the   second-line treatment of stage IV non-small cell lung cancer (NSCLC)   following disease progression after one prior platinum-based therapy.

多西他塞联合ramucirumab (RAM; IMC-1121B)对比多西他塞联合安慰剂二线治疗铂类方案进展的IV期非小细胞肺癌：一项随机、双盲、III期研究REVEL。

9:55–10:05

专家评述

Discussion Topic: A second look at anti-angiogenesis for lung cancer

讨论主题：肺癌抗血管生成治疗的再次展望

常建华(Jian-Hua Chang)

10:05–10:10

讨论(Q &   A)

陆  舜(Shun Lu)

王  洁(Jie Wang)

常建华(Jian-Hua Chang)